Search
voclosporin (Lupkynistm)
Indications:
- for use in combination with an immunosuppressive therapy regimen to treat active lupus nephritis in adult [1]
Adverse effects:
- infections (10.1% vs 11.2%)
- urinary tract infection (>3%)
- other > 3%
- renal impairment
- acute kidney injury
- decrease in glomerular filtration rate
- hypertension
- anemia
- cough
- abdominal pain, dyspepsia, diarrhea
- mouth ulceration
- decreased appetite
- fatigue
- tremor
- alopecia
Mechanism of action:
- calcineurin-inhibitor immunosuppressant
Interactions
drug adverse effects of immunosuppressive agents
monitor with immunosuppressive agents
General
calcineurin inhibitor
immunosuppressive agent
References
- FDA Approves Aurinia Pharmaceuticals' LUPKYNIS
(voclosporin) for Adult Patients with Active Lupus Nephritis
businesswire. Jan 22, 2021.
https://www.businesswire.com/news/home/20210122005501/en/FDA-Approves-Aurinia-Pharmaceuticals%E2%80%99-LUPKYNIS%E2%84%A2-voclosporin-for-Adult-Patients-with-Active-Lupus-Nephritis
- Splete H
FDA Approves Voclosporin for Lupus Nephritis
Medscape - Jan 27, 2021.
https://www.medscape.com/viewarticle/944794